Skip to main content
FUSION ANTIBODIES PLC logo

FUSION ANTIBODIES PLC — Investor Relations & Filings

Ticker · FAB ISIN · GB00BDQZGK16 LEI · 213800KBAYRC9VOQ9V39 IL Professional, scientific and technical activities
Open in API
Filings indexed 301 across all filing types
Latest filing 2024-09-09 Investor Presentation
Country GB United Kingdom
Listing IL FAB

About FUSION ANTIBODIES PLC

https://www.fusionantibodies.com/

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive suite of services for the discovery, engineering, and supply of preclinical biologics. The company offers an integrated, end-to-end antibody development platform, spanning from initial antigen design and antibody generation to advanced engineering processes like humanization and affinity maturation. It also provides services for the supply of recombinant proteins and antibodies, including stable cell line development. Fusion Antibodies supports therapeutic and diagnostic programs, operating as a collaborative partner to guide projects through critical preclinical stages with a focus on long-term manufacturability and commercialization.

Recent filings

Filing Released Lang Actions
Investor presentation
Investor Presentation Classification · 98% confidence The document is explicitly labeled as an 'RNS Number : 3023D' and a 'REACH - Non-regulatory announcement*'. The content states that management will be 'presenting at the Shard Capital Partners LLP's Investor Evening'. This describes an upcoming event where management will present information to investors, which aligns perfectly with the definition of an Investor Presentation (IP). Although it is distributed via RNS/Reach, the core subject matter is the presentation itself, not a general regulatory update or the announcement of a formal report (which would suggest RPA or RNS). The content is focused on informing investors about where and when the management presentation will occur.
2024-09-09 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official notification released via RNS (RNS Number : 1047D) dated 05 September 2024. The content explicitly details a transaction where the Chief Executive Officer, Adrian Kinkaid, purchased ordinary shares of the company. This structure—a formal announcement detailing personal share transactions by a Director/PDMR (Person Discharging Managerial Responsibilities)—perfectly matches the definition of a Director's Dealing report.
2024-09-05 English
Final Results
Earnings Release Classification · 95% confidence The document is an official announcement from Fusion Antibodies plc regarding its 'Final results' for the fiscal year ended 31 March 2024. It contains key financial highlights (revenue, cash position, orderbook), management commentary (CEO and Chairman's statements), and business performance analysis. While it is a comprehensive summary of the year's performance, it is presented as an initial 'Earnings Release' (ER) announcement via a Regulatory Information Service (RNS), which is standard for AIM-listed companies to communicate their annual results to the market before the full statutory Annual Report is filed. FY 2024
2024-09-05 English
Expansion to OptiMAL collaboration agreement
Regulatory Filings Classification · 100% confidence The document is clearly identified as an 'RNS Number' announcement from 'Fusion Antibodies PLC' dated August 28, 2024. The content describes a business update—an expansion of a collaboration agreement with the National Cancer Institute (NCI) regarding nanobodies. This is not a full financial report (10-K, IR), a specific voting result (DVA), or a management change (MANG). It is a general corporate announcement disseminated via the RNS system. The footer explicitly states, 'This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain.' While it is a non-regulatory news release, the primary identifier for this type of filing in the provided schema, especially when it's a general update distributed through the RNS mechanism, is often 'RNS' (Regulatory Filings) as the fallback for general announcements that aren't strictly regulatory disclosures like insider trades or capital changes, or it could be interpreted as a general announcement. Given the options, 'RNS' (Regulatory Filings / General regulatory announcements) is the most appropriate category for a standard, non-statutory corporate news release distributed via the RNS platform, as it is not covered by any other specific code (like ER, CAP, MANG, etc.). The document length (6031 chars) is substantial enough that it is not just a brief notice of publication (RPA).
2024-08-28 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is titled 'Director/PDMR Shareholding' and details a purchase of ordinary shares by Simon Douglas, the Non-Executive Chair. It explicitly follows the structure for 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. This type of insider transaction reporting directly corresponds to the definition of Director's Dealing (DIRS). The presence of 'RNS Number' and the footer referencing RNS and the London Stock Exchange confirms it is a regulatory disclosure, but the specific content points directly to DIRS rather than the general RNS fallback.
2024-07-22 English
Launch of New Interactive Investor Hub
Report Publication Announcement Classification · 99% confidence The document is explicitly labeled as a "REACH - Non-regulatory announcement*" and states that information required to be notified under AIM Rules or Market Abuse Regulation would be disseminated as an RNS regulatory announcement, not this one. The content announces the launch of a new 'interactive investor hub' designed to centralize regulatory announcements, reports, presentations, etc., and facilitate communication. This is a general corporate update about improving investor relations infrastructure, not a specific financial report (like 10-K, IR, ER) or a mandatory regulatory filing (like DIRS, DIV, MRQ). Since it is a general, non-mandatory corporate announcement distributed via the RNS system's non-regulatory service (Reach), the most appropriate fallback category is Regulatory Filings (RNS), as it is a general announcement distributed through the regulatory dissemination service, even if the content itself is non-regulatory news.
2024-07-18 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.